Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A large study in the United Kingdom — the PROMIS study — will shortly start to recruit patients in an attempt to see whether multi-parametric magnetic resonance imaging (MP-MRI) can help find prostate cancer and learn the extent of disease prior to prostate biopsy.
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, magnetic resonance imaging, MRI | 1 Comment »
A new paper in Urologic Oncology, taken in combination with a media release and a video release from the UCLA Health System, have described a sophisticated method of combining data from magnetic resonance imaging (MRI) of the prostate with a three-dimensional (3D) ultrasound system to optimize outcomes of prostate biopsies.
Filed under: Diagnosis, Management, Risk | Tagged: Artemis, biopsy, magnetic resonance imaging, MRI, three-dimensional, tracking, transrectal, ultrasound | Leave a Comment »
Spinal cord compression (SCC) is a major complication of metastatic castration-resistant prostate cancer (CRPC) and the onset of SCC is associated with potentially severe neurological problems.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant prostate cancer, CRPC, magnetic resonance imaging, spinal cord compression, spinal MRI | 2 Comments »
Today’s prostate cancer news reports address articles on: The role of MRI in prostate cancer diagnosis The accuracy of different types of MR imaging Removal of the seminal vesicles in surgical treatment of low-risk disease Current treatment strategies for advanced prostate cancer
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: advanced, low risk, magnetic resonance imaging, MRI, seminal vesicles, surgery | Leave a Comment »
We are returning to “normal” today with the standard “news reports.” Today’s items deal with: Evolving biomarkers and new tests and their future application MRI in diagnosis, staging, and prognosis of prostate cancer Intraprostatic injection of LHRH agonists and antagonists: is it viable? Gefitinib in HRPC: no evident impact on quality of life
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: agonist, antagonist, biomarkers, gefitinib, Iressa, LHRH, magnetic resonance imaging, MRI | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site